An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers

Trial Profile

An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Dalotuzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms COMPLETED
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Jan 2009 Actual initiation date changed from Sep 2006 to Jul 2006 as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Actual initiation date (Sep 2006) added as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top